Spruce Biosciences (SPRB) Cash & Equivalents (2019 - 2026)

Spruce Biosciences (SPRB) has reported Cash & Equivalents for 8 consecutive years, with $54.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 111.13% year-over-year to $54.1 million; the TTM figure through Mar 2026 stood at $54.1 million (up 111.13% YoY), while the FY2025 annual figure was $48.9 million, up 26.2% from the prior year.
• Cash & Equivalents rose to $54.1 million in Q1 2026 per SPRB's latest filing, from $48.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $98.8 million in Q3 2023 and bottomed at $10.7 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $52.3 million across 5 years, with a median of $48.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 84.29% — and 2023, when it soared 356.38%.
• Spruce Biosciences' Cash & Equivalents stood at $24.5 million in 2022, then surged by 293.43% to $96.3 million in 2023, then sank by 59.77% to $38.8 million in 2024, then advanced by 26.2% to $48.9 million in 2025, then grew by 10.58% to $54.1 million in 2026.
• Business Quant data shows SPRB's Cash & Equivalents at $54.1 million in Q1 2026, $48.9 million in Q4 2025, and $10.7 million in Q3 2025.